The Effect of Solifenacin on Post Void Dribbling in Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

the Percent of Patients With at Least 50% Reduction in Post Void Dribbling Episodes [ Time Frame: outcome measures will be assessed at week 0 (baseline), and compared to an average measure of weeks 10 through 12 ]

Change in Patients Perspective of the Impact of Their Disease, Captured Using the Pelvic Floor Distress Inventory (Urinary Questions) [ Time Frame: outcome measures will be assessed at week 0 (baseline), and compared to an average measure of the last 20 days on placebo or treatment ]

The difference between baseline and follow up (last 20 days on drug) scores was the recorded measure. The larger the negative # the greater the effect.

The survey was divided into 3 sections, each section worth 100 points. Total scores could range from 0 to 300 (0 no disease, 300 severe disease).

the Percent of Patients With at Least 50% Reduction in Post Void Dribbling Episodes [ Time Frame: out come measures will be assessed at week 0 (baseline), week 4, week 8, and week 12 ]

patients perspective of the impact of their disease, captured using the pelvic floor distress inventory [ Time Frame: out come measures will be assessed at week 0 (baseline), week 4, week 8, and week 12 ]

Current Other Outcome Measures ICMJE

Not Provided

Original Other Outcome Measures ICMJE

Not Provided

Descriptive Information

Brief Title ICMJE

The Effect of Solifenacin on Post Void Dribbling in Women

Official Title ICMJE

The Effect of Solifenacin on Post Void Dribbling in Women: A Randomized Controlled Multicenter Trial

Brief Summary

This is a double-blind, randomized, controlled, parallel design (n=140) study with the purpose of measuring the efficacy of Solifenacin 5mg in the treatment of women with Post Void Dribbling.

Detailed Description

This investigation will have a double-blind, randomized, and controlled, parallel design with the % reduction in post void dribbling episodes (events) as the primary endpoint.

Secondary endpoints will include:

The % of patients with at least a 50% reduction in post void dribbling episodes.

Patient's perspective of the impact of their disease, which will be captured using the Pelvic Floor Distress Inventory, and another questionnaire that asks about urinary symptoms and quality of life.

We will compare Solifenacin 5 mg to placebo. 140 subjects will be enrolled, with 70 subjects in each arm. The treatment group will receive 5mg of Solifenacin daily for 12 weeks. Astellas Pharma will be supplying both drug and placebo, they will be prepackaged and numbered. The Pharmaceutical Research Center will randomly assign subjects into the treatment vs. placebo group blinding both the subjects and investigators

Incontinence in the form of post void dribbling that occurs at least twice weekly.

Exclusion Criteria:

Severe renal or hepatic disease.

Active urinary tract infection.

Glaucoma.

Stress incontinence as the only incontinence symptom

Urge incontinence as the only incontinence symptom

Chronic severe constipation.

History of bladder cancer.

Known or suspected hypersensitivity to anticholinergics.

Any clinical condition that would not allow safe completion of the study.

Pregnancy or lactation, intention to become pregnant during the study, or use of an unreliable birth control method in women of childbearing potential. Reliable forms of contraception include: permanent sterilization of either partner, hormonal contraception (oral contraceptive, Nuva ring, contraceptive patch, depoprovera, implants), intrauterine device (IUD), and condoms. Abstinence is considered a reliable form of contraception, but abstinent subjects will be informed that they need to use condoms or other form of birth control mentioned above if they become sexually active during the study.

Presently on systemic anti-cholinergic therapy or who have been on therapy within the last 4 weeks. Anti-cholinergic drugs include; darifenacin, fesoterodine, hyoscyamine, oxybutynin, solifenacin, tolterodine, and trospium.

Solid forms of potassium supplementation, as this presents an increased risk of GI side effects.

Sex/Gender

Sexes Eligible for Study:

Female

Ages

18 Years to 89 Years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Contacts ICMJE

Contact information is only displayed when the study is recruiting subjects